Human Organic Cation Transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as Disposition Pathways for Fluoroquinolone Antimicrobials

被引:27
|
作者
Mulgaonkar, Aditi [1 ]
Venitz, Juergen [1 ]
Gruendemann, Dirk [2 ]
Sweet, Douglas H. [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA 23284 USA
[2] Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany
关键词
PHARMACOKINETICS; QUINOLONE; IDENTIFICATION; LEVOFLOXACIN; MOXIFLOXACIN; PROCAINAMIDE; SPARFLOXACIN; PREDICTION; RAT;
D O I
10.1128/AAC.02289-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fluoroquinolones (FQs) are important antimicrobials that exhibit activity against a wide range of bacterial pathogens and excellent tissue permeation. They exist as charged molecules in biological fluids, and thus, their disposition depends heavily on active transport and facilitative diffusion. A recent review of the clinical literature indicated that tubular secretion and reabsorption are major determinants of their half-life in plasma, efficacy, and drug-drug interactions. In particular, reported in vivo interactions between FQs and cationic drugs affecting renal clearance implicated organic cation transporters (OCTs). In this study, 13 FQs, ciprofloxacin, enoxacin, fleroxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, and sparfloxacin, were screened for their ability to inhibit transport activity of human OCT1 (hOCT1) (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). All, with the exception of enoxacin, significantly inhibited hOCT1-mediated uptake under initial test conditions. None of the FQs inhibited hOCT2, and only moxifloxacin inhibited hOCT3 (similar to 30%), even at a 1,000-fold excess. Gatifloxacin, moxifloxacin, prulifloxacin, and sparfloxacin were determined to be competitive inhibitors of hOCT1. Inhibition constants (K-i) were estimated to be 250 +/- 18 mu M, 161 +/- 19 mu M, 136 +/- 33 mu M, and 94 +/- 8 mu M, respectively. Moxifloxacin competitively inhibited hOCT3-mediated uptake, with a K-i value of 1,598 +/- 146 mu M. Despite expression in enterocytes (luminal), hepatocytes (sinusoidal), and proximal tubule cells (basolateral), hOCT3 does not appear to contribute significantly to FQ disposition. However, hOCT1 in the sinusoidal membrane of hepatocytes, and potentially the basolateral membrane of proximal tubule cells, is likely to play a role in the disposition of these antimicrobial agents.
引用
收藏
页码:2705 / 2711
页数:7
相关论文
共 50 条
  • [1] Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension
    Sallinen, Riitta
    Kaunisto, Mari A.
    Forsblom, Carol
    Thomas, Merlin
    Fagerudd, Johan
    Pettersson-Fernholm, Kim
    Groop, Per-Henrik
    Wessman, Maija
    [J]. ANNALS OF MEDICINE, 2010, 42 (04) : 296 - 304
  • [2] Interaction of H2-antagonists with human organic cation transporters hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
    Bourdet, DL
    Pritchard, JB
    Thakker, DR
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 262 - 262
  • [3] Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin
    Yang, Jian
    Kalogerou, Maria
    Gallacher, John
    Sampson, Julian R.
    Shen, Ming Hong
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1479 - 1490
  • [4] Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels
    Al-Eitan, Laith N.
    Almomani, Basima A.
    Nassar, Ahmad M.
    Elsaqa, Barakat Z.
    Saadeh, Nesreen A.
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2019, 9 (01):
  • [5] Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3)
    Bourdet, DL
    Pritchard, JB
    Thakker, DR
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03): : 1288 - 1297
  • [6] Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance
    Heise, Michael
    Lautem, Anja
    Knapstein, Johanna
    Schattenberg, Joern M.
    Hoppe-Lotichius, Maria
    Foltys, Daniel
    Weiler, Nina
    Zimmermann, Anca
    Schad, Arno
    Gruendemann, Dirk
    Otto, Gerd
    Galle, Peter R.
    Schuchmann, Marcus
    Zimmermann, Tim
    [J]. BMC CANCER, 2012, 12
  • [7] DOWNREGULATION OF ORGANIC CATION TRANSPORTERS OCT1 (SLC22A1) AND OCT3 (SLC22A3) IN HUMAN HEPATOCELLULAR CARCINOMA AND THEIR PROGNOSTIC SIGNIFICANCE
    Knapstein, J.
    Heise, M.
    Lautem, A.
    Schattenberg, J.
    Galle, P. R.
    Otto, G.
    Schuchmann, M.
    Zimmermann, T.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S118 - S118
  • [8] Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro
    Moss, Darren M.
    Liptrott, Neill J.
    Curley, Paul
    Siccardi, Marco
    Back, David J.
    Owen, Andrew
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (11) : 5612 - 5618
  • [9] Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance
    Michael Heise
    Anja Lautem
    Johanna Knapstein
    Jörn M Schattenberg
    Maria Hoppe-Lotichius
    Daniel Foltys
    Nina Weiler
    Anca Zimmermann
    Arno Schad
    Dirk Gründemann
    Gerd Otto
    Peter R Galle
    Marcus Schuchmann
    Tim Zimmermann
    [J]. BMC Cancer, 12
  • [10] Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes
    Cheong, Hyun Sub
    Kim, Hae Deun
    Na, Han Sung
    Kim, Ji On
    Kim, Lyoung Hyo
    Kim, Seung Hee
    Bae, Joon Seol
    Chung, Myeon Woo
    Shin, Hyoung Doo
    [J]. JOURNAL OF HUMAN GENETICS, 2011, 56 (09) : 666 - 670